Blood Advances (Feb 2018)

g(HbF): a genetic model of fetal hemoglobin in sickle cell disease

  • Kate Gardner,
  • Tony Fulford,
  • Nicholas Silver,
  • Helen Rooks,
  • Nikolaos Angelis,
  • Marlene Allman,
  • Siana Nkya,
  • Julie Makani,
  • Jo Howard,
  • Rachel Kesse-Adu,
  • David C. Rees,
  • Sara Stuart-Smith,
  • Tullie Yeghen,
  • Moji Awogbade,
  • Raphael Z. Sangeda,
  • Josephine Mgaya,
  • Hamel Patel,
  • Stephen Newhouse,
  • Stephan Menzel,
  • Swee Lay Thein

Journal volume & issue
Vol. 2, no. 3
pp. 235 – 239

Abstract

Read online

Abstract: Fetal hemoglobin (HbF) is a strong modifier of sickle cell disease (SCD) severity and is associated with 3 common genetic loci. Quantifying the genetic effects of the 3 loci would specifically address the benefits of HbF increases in patients. Here, we have applied statistical methods using the most representative variants: rs1427407 and rs6545816 in BCL11A, rs66650371 (3-bp deletion) and rs9376090 in HMIP-2A, rs9494142 and rs9494145 in HMIP-2B, and rs7482144 (Xmn1-HBG2 in the β-globin locus) to create g(HbF), a genetic quantitative variable for HbF in SCD. Only patients aged ≥5 years with complete genotype and HbF data were studied. Five hundred eighty-one patients with hemoglobin SS (HbSS) or HbSβ0 thalassemia formed the “discovery” cohort. Multiple linear regression modeling rationalized the 7 variants down to 4 markers (rs6545816, rs1427407, rs66650371, and rs7482144) each independently contributing HbF-boosting alleles, together accounting for 21.8% of HbF variability (r2) in the HbSS or HbSβ0 patients. The model was replicated with consistent r2 in 2 different cohorts: 27.5% in HbSC patients (N = 186) and 23% in 994 Tanzanian HbSS patients. g(HbF), our 4-variant model, provides a robust approach to account for the genetic component of HbF in SCD and is of potential utility in sickle genetic and clinical studies.